TEZSPIRE: Charting a New Course in Severe Asthma and Beyond

The biologics revolution in respiratory and inflammatory medicine has a compelling new chapter, and tezepelumab-ekko marketed as TEZSPIRE is one of its most closely watched protagonists. Co-developed by AstraZeneca and Amgen, this first-in-class monoclonal antibody has moved swiftly from regulatory approval to accelerating commercial momentum, reshaping how clinicians approach severe, uncontrolled asthma and now expanding its reach into additional inflammatory conditions.

A Differentiated Mechanism at the Top of the Cascade

Unlike many biologic competitors that target specific biomarkers such as IL-5 or IgE, TEZSPIRE blocks thymic stromal lymphopoietin (TSLP) an epithelial cytokine positioned upstream of both Type 2 and non-Type 2 inflammatory pathways. This broad upstream suppression means the therapy is effective regardless of a patient's eosinophil count or allergic status, a meaningful clinical distinction in a disease as phenotypically diverse as severe asthma. This breadth of efficacy is central to understanding the drug's commercial potential and forms the backbone of the TEZSPIRE Insight offered by leading market research firms.

Strong Commercial Momentum and Sales Trajectory

The commercial story has been one of rapid acceleration. In 2025, the therapy posted year-over-year sales growth of approximately 52%, while Q4 2025 alone generated around USD 474 million a 60% year-over-year surge driven primarily by volume gains. Analysts tracking the combined Amgen/AstraZeneca franchise estimate that global revenues for 2024 likely fell in the USD 1.5–2 billion range, signalling that the drug has firmly moved past its launch phase into a period of sustained, high-growth commercial uptake. The full picture of this trajectory is laid out in the TEZSPIRE Sales Forecast report from DelveInsight, which maps projected revenues across seven major markets through 2034.

Expanding Indications: A Second Growth Engine

In October 2025, the FDA approved TEZSPIRE as an add-on maintenance therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older, making it the first and only biologic approved for that indication that targets TSLP. This regulatory milestone, supported by data from the Phase III WAYPOINT trial which demonstrated significant reductions in polyp severity, nasal congestion, and need for surgery at week 52 dramatically expands the addressable patient population. Beyond CRSwNP and severe asthma, the pipeline holds potential entries into chronic obstructive pulmonary disease, eosinophilic oesophagitis, and chronic urticaria. These opportunities are carefully mapped within the broader TEZSPIRE Pipeline analysis available to market participants.

Market Size, Dynamics, and Forecast Horizon

The global severe asthma treatment market TEZSPIRE's primary arena was valued at roughly USD 24.3 billion in 2025 and is projected to grow to approximately USD 39.96 billion by 2035. This growth is underpinned by rising diagnosis rates, broader biologic uptake, and significant unmet need among refractory patients who remain inadequately controlled on existing therapies. Understanding the forces shaping this landscape requires a close reading of TEZSPIRE Market Dynamics, which encompasses competitive pressures from IL-5 antagonists and other approved biologics, physician adoption patterns, and the looming influence of late-stage pipeline entrants that could challenge market share in the medium term.

Pricing, Access, and Cost Considerations

For payers and healthcare systems evaluating treatment pathways, a thorough TEZSPIRE Cost Analysis is indispensable. Administered subcutaneously at 210 mg every four weeks via pre-filled pen or syringe, the therapy's per-patient cost varies across geographies based on reimbursement policies, national health technology assessments, and patient access programmes. TEZSPIRE Pricing strategies employed by AstraZeneca and Amgen reflect a premium positioning consistent with first-in-class status, and regional affordability considerations are expected to play an increasingly important role as the market matures and biosimilar competition begins to take shape in the longer term.

Competitive Landscape and Strategic Outlook

Despite its strong positioning, tezepelumab-ekko faces a well-established competitive field that includes mepolizumab, benralizumab, dupilumab, and other biologics with firm market footholds. Its key differentiator the biomarker-agnostic broad label provides a meaningful advantage for patients who do not qualify under more restrictive eligibility criteria. As biosimilar timelines and patent landscapes evolve, the drug's long-term market position will depend on its ability to sustain clinical differentiation, demonstrate real-world value, and successfully execute on its expanding indication strategy. DelveInsight's comprehensive analysis tracks all of these dimensions, equipping strategic decision-makers with the granular intelligence needed to navigate a rapidly evolving immunology market.